Further, both SERMS and AIs have been shown to confer substantial protection (>50%) against ER+ breast cancer development leading to FDA approval of tamoxifen and raloxifene to reduce BC risk in women at high risk of BC development [10–13]. This evidence concerns the gene ESR1 and breast carcinoma.